See more : Asana, Inc. (ASAN) Income Statement Analysis – Financial Results
Complete financial analysis of Aptorum Group Limited (APM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aptorum Group Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Urja Global Limited (URJAGLOBA.BO) Income Statement Analysis – Financial Results
- Therapeutics Acquisition Corp. (RACA) Income Statement Analysis – Financial Results
- Ameritrans Capital Corp. PFD PRT 9.375% (AMTPQ) Income Statement Analysis – Financial Results
- Hudson Executive Investment Corp. (HECCU) Income Statement Analysis – Financial Results
- TVS Srichakra Limited (TVSSRICHAK.NS) Income Statement Analysis – Financial Results
Aptorum Group Limited (APM)
About Aptorum Group Limited
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 431.38K | 1.30M | 1.54M | 911.51K | 535.17K | 383.45K | 0.00 |
| Cost of Revenue | 420.81K | 1.22M | 1.46M | 1.02M | 794.55K | 318.01K | 58.90K |
| Gross Profit | 10.57K | 80.07K | 81.85K | -103.51K | -259.38K | 65.44K | -58.90K |
| Gross Profit Ratio | 2.45% | 6.18% | 5.31% | -11.36% | -48.47% | 17.07% | 0.00% |
| Research & Development | 5.20M | 9.22M | 10.87M | 11.59M | 6.94M | 3.10M | 2.50M |
| General & Administrative | 4.37M | 7.87M | 7.70M | 7.71M | 10.78M | 6.73M | 0.00 |
| Selling & Marketing | 48.98K | 98.08K | 95.95K | 55.43K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.41M | 7.97M | 7.80M | 7.71M | 10.78M | 6.73M | 2.88M |
| Other Expenses | -9.60M | 404.54K | 623.64K | 877.39K | 220.89K | 560.71K | -257.18K |
| Operating Expenses | 10.57K | 17.59M | 19.29M | 20.17M | 17.94M | 10.39M | 5.63M |
| Cost & Expenses | 10.95M | 18.81M | 20.75M | 21.19M | 18.73M | 10.71M | 5.69M |
| Interest Income | 0.00 | 146.59K | 0.00 | 0.00 | 0.00 | 0.00 | 44.27K |
| Interest Expense | 121.15K | 146.59K | 93.60K | 243.63K | 3.70M | 4.46M | 0.00 |
| Depreciation & Amortization | 1.13M | 1.21M | 1.19M | 1.33M | 1.30M | 682.29K | 58.90K |
| EBITDA | -9.60M | -17.59M | -19.29M | 6.50M | -15.12M | -9.99M | -2.50M |
| EBITDA Ratio | -2,225.19% | -1,678.81% | -1,158.95% | -2,034.44% | -3,443.92% | -2,424.73% | 0.00% |
| Operating Income | -10.52M | -22.96M | -19.06M | -19.88M | -19.73M | -10.33M | -5.69M |
| Operating Income Ratio | -2,439.47% | -1,771.99% | -1,236.31% | -2,180.86% | -3,686.76% | -2,693.47% | 0.00% |
| Total Other Income/Expenses | 6.18M | 6.06M | -7.91M | 25.20M | -1.92M | -4.81M | 3.13M |
| Income Before Tax | -4.34M | -11.53M | -27.11M | 4.92M | -20.12M | -15.13M | -2.56M |
| Income Before Tax Ratio | -1,006.30% | -889.36% | -1,758.64% | 539.78% | -3,759.01% | -3,946.93% | 0.00% |
| Income Tax Expense | 0.00 | -6.21M | -1.83M | -1.51M | 737.64K | -302.76K | -14.05K |
| Net Income | -2.82M | -5.31M | -25.29M | 7.07M | -20.85M | -14.83M | -2.55M |
| Net Income Ratio | -654.80% | -410.10% | -1,640.21% | 775.29% | -3,896.84% | -3,867.97% | 0.00% |
| EPS | -0.62 | -14.89 | -7.22 | 2.03 | -7.19 | -5.31 | -0.85 |
| EPS Diluted | -0.62 | -14.89 | -7.22 | 2.00 | -7.19 | -5.31 | -0.85 |
| Weighted Avg Shares Out | 4.52M | 356.95K | 3.50M | 3.11M | 2.90M | 2.79M | 3.01M |
| Weighted Avg Shares Out (Dil) | 4.52M | 356.95K | 3.50M | 3.15M | 2.90M | 2.79M | 3.01M |
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
5 Investors Betting Big on Aptorum (APM) Group
Why Is Aptorum (APM) Stock Up 346% Today?
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
Why Is Aptorum (APM) Stock Down 16% Today?
Aptorum Group shares double after merger plans, earnings delight investors
Source: https://incomestatements.info
Category: Stock Reports